[Clinical application and optimization of HEAD-US quantitative ultrasound assessment scale for hemophilic arthropathy]

Clinical analysis and quality of life survey of hemophilia B patients in the central and western regions of China

Objective

To study the current status of hemophilia B (HB) patients in the central and western regions of China.

Methods

This cross-sectional, multicenter study was conducted in seven provinces in the central and western regions of China from April 2019 to June 2023. Samples were collected for the factor IX activity, inhibitor screen, and gene mutation. Furthermore, the status of six index joints and quality of life (QoL) were assessed.

Results

A total of 185 HB patients (mild 15, moderate 75, and severe 95) with a median age of 12.17 years were enrolled. 30.3% (56/185) of patients had a family history of HB. 34.6% (64/185) of HB patients had diagnostic delay and 38.5% (69/179) experienced treatment delay. The incidence of inhibitors was 6.1% (11/179). We identified 123 genetic variants in this study, with missense mutations being the most common. 84.0% (89/106) of HB mothers were genetically identified as carriers, with 27.7% (13/47) of carriers having clotting factor levels less than 0.40 IU/ml. 71.4% (132/185) of HB patients had a history of joint hemorrhage, with a rate of target joint in these patients was 64.4% (85/132). Lower extremity joints were most often affected in patients. The Hemophilia Joint Health Score (HJHS) score was significantly positively correlated with the Hemophilia Early Arthropathy Detection with Ultrasound in China (HEAD-US-C) (r = 0.542, P < 0.001). Patients who received prevention treatment, inhibitor negative, without treatment delay, and without high-intensity replacement therapy showed a higher total score of the short form-36 health survey (SF-36).

Conclusions

One-third of HB patients had delay in diagnosis and treatment, and the incidence of inhibitors was 6.1%. Target joints were present in nearly half of HB patients. Missense was the main mutation type. 84.0% of mothers of HB patients in this study were found to be carriers. HEAD-US-C and HJHS can complement each other in the evaluation of joint status and give a valid basis for early clinical management. Early detection and preventive treatment, as well as reducing high-intensity replacement therapy and inhibitor generation, can effectively improve the QoL of patients.

[Clinical study on factor Ⅷ inhibitor in children with hemophilia A]

目的

探讨血友病A（HA）患儿凝血因子Ⅷ（FⅧ）抑制物产生的相关因素及抑制物产生前后出血与关节病表现的差异。

方法

对2015年1月至2018年8月河南省血友病管理中心登记收治的381例16岁以下HA患儿进行回顾性分析。

结果

381例HA患儿中，轻型116例（30.4%），中间型196例（51.4%），重型69例（18.1%）。FⅧ抑制物阳性患者54例（14.2%），高滴度、低滴度分别为22、32例。血友病家族史与FⅧ抑制物阳性相关[P<0.001，OR=3.299（95%CI 1.743~5.983）]；高强度暴露与FⅧ抑制物的产生相关[P=0.002，OR=2.587（95%CI 1.414~4.731）]。高强度暴露与高滴度FⅧ抑制物产生相关[P=0.001，OR=8.689（95%CI 2.464~30.638）]。54例HA患者产生抑制物后，总体关节年出血率、创伤性年出血率增加（z=−3.440，P=0.001；z=−2.232，P=0.026），而非关节年出血率、自发性年出血率与抑制物产生前比较差异无统计学意义（z=−1.342，P=0.180；z=−1.414，P=0.157）。关节超声评分较产生抑制物前差异无统计学意义（z=−0.632，P=0.527）。

结论

血友病家族史、高强度暴露可增加HA患儿发生FⅧ抑制物的风险，且高强度暴露可增加HA患者出现高滴度抑制物的风险。

A Translational Study of TNF-Alpha Antagonists as an Adjunctive Therapy for Preventing Hemophilic Arthropathy

Repeated intra-articular hemorrhages lead to hemophilic arthropathy in severe hemophilia. Inflammation and pro-inflammatory cytokines (e.g., tumor necrosis factor alpha (TNFα)) might be involved in this pathogenesis. We hypothesized that anti-TNFα may provide adjuvant protection for hemophilic arthropathy management. We measured TNFα in synovial lavage from hemophilia mice subjected to hemarthrosis induction and synovial fluid from patients with hemophilic arthropathy (n = 5). In hemophilia mice, recurrent hemarthroses were induced, anti-TNFα was initiated either from day (D)7 after one hemarthrosis episode or D21 after three hemarthroses episodes (n ≥ 7/treatment group). In patients with hemophilic arthropathy (16 patients with 17 affected joints), a single dose of anti-TNFα was administered intra-articularly. Efficacy, characterized by synovial membrane thickness and vascularity, was determined. Elevated TNFα in synovial lavage was found in the hemophilia mice and patients with hemophilic arthropathy. Hemophilia mice subjected to three hemarthroses developed severe synovitis (Synovitis score of 6.0 ± 1.6). Factor IX (FIX) replacement alone partially improved the pathological changes (Synovitis score of 4.2 ± 0.8). However, anti-TNFα treatment initiated at D7, not D21, significantly provided protection (Synovitis score of 1.8 ± 0.9 vs. 3.9 ± 0.3). In patients with hemophilic arthropathy, intra-articular anti-TNFα significantly decreased synovial thickness and vascularity during the observed period from D7 to D30. Collectively, this preliminary study seems to indicate that TNFα may be associated with the pathogenicity of hemophilic arthropathy and anti-TNFα could provide adjuvant protection against hemophilic arthropathy. Further studies are required to confirm the preliminary results shown in this study.

[HEAD-US-C quantitative ultrasound assessment scale in evaluation of joint damage in patients with moderate or severe hemophilia A received on-demand versus prophylaxis replacement therapy]

目的

探讨血友病关节超声评估量表（Haemophilic Early Arthropathy Detection with UltraSound in China，HEAD-US-C）对中间型/重型血友病A患者按需、预防治疗关节损伤评估的适用性。

方法

回顾性分析2015年6月至2017年7月70例接受肘、膝、踝关节超声检查的中间型及重型血友病A患者，应用HEAD-US-C超声评估量表及血友病关节健康评分量表2.1版（HJHS2.1）进行关节状况评分。对按需、预防治疗患者HEAD-US-C、HJHS评分进行相关性分析。

结果

70例中间型及重型血友病A患者共接受919例次关节超声检查。在中间型血友病患者中，按需、预防治疗组患者中位年靶关节出血次数差异无统计学意义[1（0，7）对1（0，5），z=1.271，P=0.137]。按需治疗组中位HEAD-US-C评分[1（0，6）对0.5（0，3），z=0.177，P=0.046]及HJHS评分[2（0，4）对2（0，3），z=0.375，P=0.007]明显高于预防治疗组。重型血友病患者按需、预防治疗组中位HEAD-US-C评分分别为4（0，7）、1（0，6）（z=2.189，P=0.008），中位HJHS评分分别为4（1，6）、2（0，5）（z=3.646，P<0.001），年靶关节出血次数分别为3（0，8）、2（0，8）（z=0.780，P=0.037），按需治疗组均高于预防治疗组。按需、预防治疗组患者HEAD-US-C评分与HJHS评分均存在正相关关系（P值均<0.05）。重型患者按需、预防治疗组HEAD-US-C评分与HJHS评分的相关系数分别为0.739（95%CI 0.708~0.767）、0.865（95%CI 0.848~0.880），95%CI不重合（P<0.05），预防治疗组两评分系统间具有更强的相关性。

结论

中间型/重型血友病A患者预防治疗疗效明显优于按需治疗。HEAD-US-C超声评估量表可有效评估中间型/重型血友病A患者按需、预防治疗关节损伤状况，与HJHS系统一致性较好，可为临床疗效评估提供客观指标。